Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Pang, Jia Min B ^a,b   Deb, Siddhartha ^a,b   Takano, Elena A ^a   Byrne, David J ^a   Jene, Nicholas ^a   Boulghourjian, Alice ^c   Holliday, Anne ^c   Millar, Ewan ^c,d,e,g   Soon Lee, C ^f,g,h   O'Toole, Sandra A ^c,f,i   Dobrovic, Alexander ^a,b,j   Fox, Stephen B ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d ST GEORGE HOSPITAL   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF WESTERN SYDNEY   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BRCA1 PROTEIN; CADHERIN; CADHERIN 13; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; FORMALDEHYDE; PARAFFIN; PROGESTERONE RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; APC GENE; ARTICLE; BREAST BIOPSY; BREAST EPITHELIUM; CANCER CLASSIFICATION; CANCER GRADING; CDH13 GENE; CLINICAL FEATURE; CLUSTER ANALYSIS; COMEDO NECROSIS; CONTROLLED STUDY; CPG ISLAND; DNA EXTRACTION; DNA METHYLATION; EMBEDDING; ERALPHA GENE; GENE; GENE AMPLIFICATION; GENETIC ASSOCIATION; HER2 GENE; HIGH RESOLUTION MELTING ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MICRODISSECTION; MIDDLE AGED; PGR GENE; PHENOTYPE; PROMOTER REGION; RARALPHA GENE; RARBETA GENE; RASSF1A GENE; TISSUE NECROSIS; TUMOR SUPPRESSOR GENE; VERY ELDERLY; BREAST TUMOR; DNA SEQUENCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; PHENOTYPE; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 84988844510     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-014-0423-9     Document Type: Article

References (54)

1. Wang SY, Shamliyan T, Virnig BA, Kane R: Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 2011, 127:1-14.
2. Lari SA, Kuerer HM: Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer 2011, 2:232-261.
3. Independent UKPoBCS: The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786.
4. Heichman KA, Warren JD: DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med 2012, 50:1707-1721.
5. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH: Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 2011, 458:73-84.
6. Lee JS, Fackler MJ, Teo WW, Lee JH, Choi C, Park MH, Yoon JH, Zhang Z, Argani P, Sukumar S: Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther 2008, 7:1398-1406.
7. Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Borresen-Dale AL, Kristensen VN, Sorlie T, Tost J: Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 2010, 12:R3.
8. Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, Lonning PE, Solvang H, Borresen-Dale AL, Tost J, Kristensen VN: Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 2013, 13:456.
9. Moelans CB, Verschuur-Maes AH, van Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 2011, 225:222-231.
10. Lehmann U, Langer F, Feist H, Glockner S, Hasemeier B, Kreipe H: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 2002, 160:605-612.
11. Pang JMB, Dobrovic A, Fox SB: DNA methylation in ductal carcinoma in situ of the breast. Breast Cancer Res 2013, 15:3.
12. Cancer Genome Atlas N: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
13. Wu L, Wang F, Xu R, Zhang S, Peng X, Feng Y, Wang J, Lu C: Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis. Breast Cancer Res Treat 2013, 142:619-627.
14. Xu X, Gammon MD, Zhang Y, Bestor TH, Zeisel SH, Wetmur JG, Wallenstein S, Bradshaw PT, Garbowski G, Teitelbaum SL, Neugut AI, Santella RM, Chen J: BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009, 115:397-404.
15. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y: Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007, 9:R57.
16. Horne HN, Lee PS, Murphy SK, Alonso MA, Olson JA Jr, Marks JR: Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol Cancer Res 2009, 7:199-209.
17. Cheol Kim D, Thorat MA, Lee MR, Cho SH, Vasiljevic N, Scibior-Bentkowska D, Wu K, Ahmad AS, Duffy S, Cuzick JM, Lorincz AT: Quantitative DNA methylation and recurrence of breast cancer: a study of 30 candidate genes. Cancer Biomark 2012, 11:75-88.
18. Trifa F, Karray-Chouayekh S, Jmal E, Jmaa ZB, Khabir A, Sellami-Boudawara T, Frikha M, Daoud J, Mokdad-Gargouri R: Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients. Tumour Biol 2013, 34:1625-1633.
19. Schnitt SJ AC, Britton P, Ellis IO, Lakhani SR, Morrow M, Palazzo J, Reynolds C, Rutgers E, Simpson J, van de Vijver MJ, Vincent-Salomon A: Ductal carcinoma in situ. In WHO classification of tumours of the breast. 4th edition. Edited by Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ. Lyon: International Agency for Research on Cancer; 2012:90-94.
20. Yan M, Xu H, Waddell N, Shield-Artin K, Haviv I, kConFab a, McKay MJ, Fox SB: Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers. Breast Cancer Res 2012, 14:R69.
21. Deb S, Jene N, Kconfab I, Fox SB: Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer 2012, 12:510.
22. WolffAC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical O, College of American P: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
23. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
24. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
25. Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL: Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011, 104:120-127.
26. Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC: Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007, 38:197-204.
27. Zhou W, Jirstrom K, Johansson C, Amini RM, Blomqvist C, Agbaje O, Warnberg F: Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer 2010, 10:653.
28. Huang KT, Dobrovic A, Yan M, Karim RZ, Lee CS, Lakhani SR, Fox SB: DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. Breast Cancer Res Treat 2010, 124:555-565.
29. Wojdacz TK, Dobrovic A: Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007, 35:e41.
30. Mikeska T, Dobrovic A: Methylation-sensitive high resolution melting for the rapid analysis of DNA methylation. In Epigenetics: a reference manual. Edited by Craig JaW NC. Norwich: Horizon Scientific Press; 2011:325-335.
31. Candiloro IL, Mikeska T, Dobrovic A: Assessing combined methylation-sensitive high resolution melting and pyrosequencing for the analysis of heterogeneous DNA methylation. Epigenetics 2011, 6:500-507.
32. Wojdacz TK, Hansen LL, Dobrovic A: A new approach to primer design for the control of PCR bias in methylation studies. BMC Res Notes 2008, 1:54.
33. Fackler MJ, Malone K, Zhang Z, Schilling E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE, Khan SA, Sukumar S: Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res 2006, 12:3306-3310.
34. Yan PS, Venkataramu C, Ibrahim A, Liu JC, Shen RZ, Diaz NM, Centeno B, Weber F, Leu YW, Shapiro CL, Eng C, Yeatman TJ, Huang TH: Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res 2006, 12:6626-6636.
35. van Hoesel AQ, Sato Y, ElashoffDA, Turner RR, Giuliano AE, Shamonki JM, Kuppen PJ, van de Velde CJ, Hoon DS: Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer 2013, 108:2033-2038.
36. Verschuur-Maes AH, de Bruin PC, van Diest PJ: Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer. Breast Cancer Res Treat 2012, 136:705-715.
37. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A: Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000, 21:147-151.
38. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997, 349:1505-1510.
39. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Ford D, Peto J, Stoppa-Lyonnet D, Bignon YJ, Struewing JP, Spurr NK, Bishop DT, Klijn JG, Devilee P, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145.
40. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, Shen R, Seshan V, Mo Q, Heguy A, Baylin SB, Ahuja N, Viale A, Massague J, Norton L, Vahdat LT, Moynahan ME, Chan TA: Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci Transl Med 2011, 3:75ra25.
41. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, Olsson H, Borg A, Ringner M: Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 2010, 12:R36.
42. Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T: Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Res Treat 2013, 142:365-380.
43. Suijkerbuijk KP, Fackler MJ, Sukumar S, van Gils CH, van Laar T, van der Wall E, Vooijs M, van Diest PJ: Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann Oncol 2008, 19:1870-1874.
44. Klarmann GJ, Decker A, Farrar WL: Epigenetic gene silencing in the Wnt pathway in breast cancer. Epigenetics 2008, 3:59-63.
45. Andreeva AV, Kutuzov MA: Cadherin 13 in cancer. Genes Chromosomes Cancer 2010, 49:775-790.
46. Alvarez S, Germain P, Alvarez R, Rodriguez-Barrios F, Gronemeyer H, de Lera AR: Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor. Int J Biochem Cell Biol 2007, 39:1406-1415.
47. Agathanggelou A, Cooper WN, Latif F: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005, 65:3497-3508.
48. Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R: Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol 2012, 19:3107-3115.
49. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, Ralhan R: Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol 2009, 31:487-500.
50. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003, 63:7641-7645.
51. Muller HM, Fiegl H, Widschwendter A, Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Ann NY Acad Sci 2004, 1022:44-49.
52. Jiang Y, Cui L, Chen WD, Shen SH, Ding LD: The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One 2012, 7:e36780.
53. Xu J, Shetty PB, Feng W, Chenault C, Bast RC Jr, Issa JP, Hilsenbeck SG, Yu Y: Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer 2012, 12:243.
54. Harbeck N, Nimmrich I, Hartmann A, Ross JS, Cufer T, Grutzmann R, Kristiansen G, Paradiso A, Hartmann O, Margossian A, Martens J, Schwope I, Lukas A, Muller V, Milde-Langosch K, Nahrig J, Foekens J, Maier S, Schmitt M, Lesche R: Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients. J Clin Oncol 2008, 26:5036-5042.